Last reviewed · How we verify
Cisplatin-Gemzar
Cisplatin-Gemzar works by inhibiting DNA replication and interfering with the synthesis of DNA and RNA, ultimately leading to cell death.
Cisplatin-Gemzar works by inhibiting DNA replication and interfering with the synthesis of DNA and RNA, ultimately leading to cell death. Used for Advanced ovarian cancer, Pancreatic cancer.
At a glance
| Generic name | Cisplatin-Gemzar |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Drug class | Platinum-based chemotherapy and nucleoside analog |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Cisplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, which interfere with DNA replication and transcription. Gemzar, also known as gemcitabine, is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA and causing chain termination. The combination of these two drugs targets rapidly dividing cancer cells.
Approved indications
- Advanced ovarian cancer
- Pancreatic cancer
Common side effects
- Nausea and vomiting
- Fatigue
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery (PHASE2)
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) (PHASE2)
- MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (PHASE2)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cisplatin-Gemzar CI brief — competitive landscape report
- Cisplatin-Gemzar updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI